|

Furmonertinib Clinical Trials

12 actively recruiting trials

▲ +2 trials since August 2026

Also known as: AST2818, Furmonertinib Mesylate, Furmonertinib(AST2818), Ivesa, bevacizumab +1 more

Pipeline

Phase 2: 8Phase 3: 1Phase 1/2: 2

Top Sponsors

  • Tianjin Medical University Cancer Institute and Hospital1
  • Sun Yat-sen University1
  • Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.1
  • Shanghai Zhongshan Hospital1
  • Shanghai Pulmonary Hospital, Shanghai, China1

Indications

  • Cancer12
  • Lung Cancer11
  • Non Small Cell Lung Cancer8
  • EGFR Gene Mutation2
  • Lung Adenocarcinoma Stage IV1

Other12 trials

A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer
Phase 1/2
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
Phase 2
Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
N/A
Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations
Phase 3
Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
Phase 2
Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA
Phase 2
High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases
Phase 2
High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib
Phase 2
IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
Phase 1/2
Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung Adenocarcinoma
Phase 2
Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC
Phase 2
To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.